Australia’s biotech giant CSL Seqirus has officially opened a state-of-the-art manufacturing facility in Melbourne — a A$1 billion investment aimed at producing next-generation cell-based influenza vaccines, antivenoms and the country’s only human Q-fever vaccine.

The plant, unveiled on December 2, 2025, marks a sharp departure from the company’s traditional egg-based production site in Parkville, ending an 80-year legacy.

:contentReference[oaicite:1]{index=1}

Spanning some 28,400 square metres near Tullamarine airport, the new facility is equipped to meet seasonal flu demands for Australia and export markets across Asia, Europe, the Middle East and the Americas.

CSL says the site will support an annual supply-chain contribution of roughly A$300 million to the Australian economy.

:contentReference[oaicite:2]{index=2}

By leveraging cell-based vaccine technology — considered faster and more scalable than traditional methods — the plant positions Australia among only three countries worldwide capable of full end-to-end cell-based influenza vaccine production.

It will also manufacture all of the nation’s antivenoms for venomous snakes, spiders and marine creatures, reinforcing a long-standing domestic public-health commitment.

:contentReference[oaicite:3]{index=3}

CSL’s Chief Executive described the investment as both a public-health milestone and a boost for Australian biotech manufacturing.

Government officials echoed that, saying the plant strengthens national pandemic preparedness and reduces reliance on overseas supply chains.

:contentReference[oaicite:4]{index=4}

Yet the future of CSL Seqirus remains uncertain.

Earlier this year, the company paused plans to sell the vaccine business, raising questions about long-term strategy and financial viability.

Some analysts and industry observers say the new facility underscores CSL’s renewed commitment — but they note that global demand for flu vaccines and antivenoms can fluctuate significantly, leaving financial outcomes hard to predict.

:contentReference[oaicite:5]{index=5}

For now, the Melbourne plant stands as a symbol of Australia’s ambition to secure sovereign control over critical medicines, and a tangible step toward stronger pandemic resilience and global health contribution.